Modulation of vascular healing by inhibition of leukocyte adhesion and function
CA 2288198 A1 · Owner: Massachusetts Institute Of Technology · Inventors: Edelman, Elazer R.; Rogers, Campbell; Simon, Daniel I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds that specifically inhibit or reduce leukocyte adhesion or function are useful to enhance vascular healing and lessen restenosis of blood vessels after revascularization, via angioplasty or bypass surgery of diseased , coronary, peripheral and cerebral arteries and lessen stenosis or restenosis , of surgically-placed bypass grafts and transplanted organs. Examples of these compounds are those which block cell surface integrins or their ligands for , example, the leukocyte integrin Mac-1 (CD11b/CD18 .alpha.M.beta.2). As , demonstrated by the examples both superficial and deep injury was , significantly reduced with treatment using an antibody to Mac-1 compared to both saline …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 25, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 25, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 25, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.